Provided by Tiger Trade Technology Pte. Ltd.

Agenus

3.44
-0.1200-3.37%
Post-market: 3.510.0700+2.03%18:13 EDT
Volume:252.27K
Turnover:872.98K
Market Cap:132.09M
PE:-1.01K
High:3.52
Open:3.50
Low:3.41
Close:3.56
52wk High:7.34
52wk Low:1.38
Shares:38.40M
Float Shares:35.64M
Volume Ratio:0.71
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0034
EPS(LYR):-10.5913
ROE:-1278.83%
ROA:-5.67%
PB:-0.49
PE(LYR):-0.32

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:33 AM

Reuters
·
Dec 19, 2025

Agenus Drops in Volume Spike, Last Down 5.1%

THOMSON REUTERS
·
Dec 03, 2025

Agenus Inc. Hosts Stakeholder Webcast Showcasing BOT/BAL Progress and GI Oncology Advances

Reuters
·
Nov 20, 2025

Agenus appoints Jose Iglesias as chief medical affairs officer

TIPRANKS
·
Nov 18, 2025

BRIEF-Agenus Appoints Dr. José Iglesias As Chief Medical Affairs Officer To Guide Global Medical Affairs And Early-Access Programs, Including France’S Aac

Reuters
·
Nov 18, 2025

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer

Reuters
·
Nov 18, 2025

Agenus Appoints DR. JosÉ Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

THOMSON REUTERS
·
Nov 18, 2025

Agenus Inc Qtrly Shr USD 1.94

THOMSON REUTERS
·
Nov 10, 2025

Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate

Benzinga
·
Nov 10, 2025

Agenus reports Q3 net income of $63.9 million on revenue of $30.2 million

Reuters
·
Nov 10, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025

Agenus Inc expected to post earnings of $1.98 a share - Earnings Preview

Reuters
·
Nov 07, 2025

Press Release: Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Dow Jones
·
Nov 06, 2025

Agenus Inc. Advances Cancer Treatment with Promising Study Update

TIPRANKS
·
Oct 28, 2025

Promising Clinical Trial Results Support Buy Rating for Agenus’s Botensilimab and Balstilimab Therapy

TIPRANKS
·
Oct 17, 2025

Agenus Reports 39% Two-Year Survival with BOT/BAL Immunotherapy Across Multiple Refractory Solid Tumors at ESMO 2025

Reuters
·
Oct 17, 2025

Agenus Reports 39% of Patients Alive at Two-Years With BOT/Bal Across Multiple Refractory Solid Tumors at Esmo 2025

THOMSON REUTERS
·
Oct 17, 2025

Agenus Secures 10 Million Loan from Zydus Backed by MiNK Therapeutics Shares

Reuters
·
Oct 10, 2025